Born in California, Dr. Hyman has lived in Texas since the fourth grade. During medical school in Houston and residency in Cincinnati, mentors in Hematology-Oncology impressed him in their care of the whole patient and their families. This led to a return to the Texas Medical Center for fellowship in Medical Oncology. Dr. Hyman spent the first 28 years of his career in Tyler, Texas, practicing general adult Medical Oncology. He was instrumental at developing and opening the UT Health Northeast MD Anderson Cancer Center, the first full MD Anderson Network partnership in Texas, and becoming the inaugural Medical Director.
He comes to UT Southwestern to return to the bedside and to full time patient care, as a dedicated Oncology Hospitalist for the Solid Tumor Inpatient Service at William P. Clements, Jr. University Hospital, capitalizing on his vast experience in care of patients with cancers in all disease sites.
Dr. Hyman and his wife enjoy exploring the Dallas area, especially visiting antique stores, and spending time spoiling their 3 grandkids.
- Medical School
- Baylor College of Medicine (1985)
- University of Cincinnati Medical Center (1988), Internal Medicine
- Baylor College of Medicine (1990), Medical Oncology
- Phase I-III Clinical Trials Testing New Therapies for Treating Cancer
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
- Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L Invest New Drugs 2012 Jun 30 3 1232-40
- Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
- Richards DA, Loesch D, Vukelja SJ, Wu H, Hyman WJ, Nieves J, Wang Y, Hu S, Shonukan OO, Tai DF Invest New Drugs 2011 Oct 29 5 963-70
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
- Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA J. Clin. Oncol. 2009 Mar 27 8 1177-83
- Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
- Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL, Boehm KA, Asmar L Clin Colorectal Cancer 2008 Nov 7 6 390-7
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
- Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L J. Clin. Oncol. 2006 Dec 24 34 5381-7
- Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
- Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L Clin Lymphoma 2003 Dec 4 3 169-75
- Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
- Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M J. Clin. Oncol. 1999 Oct 17 10 3025-32
- SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trial.
- Nemunaitis J, Martin DE, Willis DL, Freed MI, Levitt B, Richards DA, Cox JV, Kimmel GT, Hyman WJ, Jorkasky DK, Brocks DR Am. J. Clin. Oncol. 1998 Apr 21 2 189-94
- American College of Physicians (2014)
- American Society of Clinical Oncology (1989)